Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
Looking ahead, BofA cut its 2025 and 2026 revenue forecasts by 18% and 15%, respectively. While negative EPS projections ...
An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...
We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...
Janney Montgomery Scott LLC lowered its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 21.0% in the fourth quarter, ...
Inflation data, Powell testimony, more earnings will be in focus this week. • Robinhood’s strong financial health, robust ...
BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $34 from $41 and keeps an Underperform rating on the shares ...
As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...
To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...
The claim that Moderna’s CEO confessed to creating a COVID vaccine before the pandemic is false. His remarks at Davos 2023 ...
Moderna stock tumbled after the Senate Finance Committee voted to send RFK Jr.'s nomination for the HHS secretary to the full ...
AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results